NIPH Clinical Trials Search

UMIN ID: UMIN000002287

Registered date:03/08/2009

A phase2 study of Rituximab+THP-COP(R-THP-COP) in elderly subjects with untreated, advanced, CD20-positive, indolent B-cell Non-Hodgkin's lymphoma

Basic Information

Recruitment status Complete: follow-up continuing
Health condition(s) or Problem(s) studiedindolent B-cell lymphoma
Date of first enrollment2005/05/01
Target sample size40
Countries of recruitmentJapan
Study typeInterventional


Primary OutcomeComplete response rate,safty
Secondary Outcomeoverall response rate,progression-free survival,overall survival,safty

Key inclusion & exclusion criteria

Age minimum70years-old
Age maximum79years-old
GenderMale and Female
Include criteria
Exclude criteria1.Central nervous system(CNS) NHL 2.Current or chronic hepatitis B or C infection;known seropositiviry for human immunodeficiency virus(HIV). 3.Any evidence of serious active infection 4.Unstable or severe uncontrolled medical condition or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk associated with the subject's participation in the study.

Related Information


public contact
Name Kazunori Ohnishi
Address 1-20-1handayama,higashiku,hamamatsu,shizuoka Japan
Telephone 053-435-2267
Affiliation Hamamatsu University school of Medicine Oncology center
scientific contact
Name Michinori Ogura
Address 2-9 myoukencho,Showa,nagoya,aichi Japan
Telephone 052-832-1121
Affiliation Nagoya daini red cross hospital hematology